The pandemic trigged an “astonishing” surge in the biotech industry, with red-hot stock valuations and a flood of IPOs.
Published on 13th February 2022
The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.
An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.
The material on this website is intended to be viewed only by persons resident in the UK.
The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.
No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.
The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).